ATE285076T1 - Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren - Google Patents

Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren

Info

Publication number
ATE285076T1
ATE285076T1 AT97937333T AT97937333T ATE285076T1 AT E285076 T1 ATE285076 T1 AT E285076T1 AT 97937333 T AT97937333 T AT 97937333T AT 97937333 T AT97937333 T AT 97937333T AT E285076 T1 ATE285076 T1 AT E285076T1
Authority
AT
Austria
Prior art keywords
interferon
activity
expression
test sample
molt4
Prior art date
Application number
AT97937333T
Other languages
English (en)
Inventor
Rajko D Medenica
David K Powell
Original Assignee
Shaker Ghassan I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaker Ghassan I filed Critical Shaker Ghassan I
Application granted granted Critical
Publication of ATE285076T1 publication Critical patent/ATE285076T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/565—IFN-beta
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97937333T 1996-08-19 1997-08-19 Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren ATE285076T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2417396P 1996-08-19 1996-08-19
PCT/US1997/014658 WO1998008099A1 (en) 1996-08-19 1997-08-19 Use of molt4 cd69 expression to determine the presence and activity of interferon inhibitors

Publications (1)

Publication Number Publication Date
ATE285076T1 true ATE285076T1 (de) 2005-01-15

Family

ID=21819236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97937333T ATE285076T1 (de) 1996-08-19 1997-08-19 Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren

Country Status (6)

Country Link
US (1) US5989839A (de)
EP (1) EP1021726B1 (de)
AT (1) ATE285076T1 (de)
AU (1) AU3986697A (de)
DE (1) DE69731983T2 (de)
WO (1) WO1998008099A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2330291C1 (ru) * 2007-02-26 2008-07-27 ГУ Научно-исследовательский институт медицинских проблем Севера СО РАМН Способ прогнозирования развития атопического дерматита у новорожденных
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
CN113597532B (zh) 2019-03-14 2023-02-17 泰尔茂比司特生物技术有限公司 冻干容器填充固定装置、系统及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU648022B2 (en) * 1989-03-14 1994-04-14 Bionebraska, Inc. Monoclonal antibodies for metallic cations on small molecules
US5270037A (en) * 1990-07-12 1993-12-14 Boehringer Ingelheim Gmbh Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL106591A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
WO1994010188A1 (en) * 1992-10-29 1994-05-11 Immunex Corporation Activation antigen cd69
WO1995000529A1 (en) * 1993-06-18 1995-01-05 Pharmagenics, Inc. INHIBITION OF INTERFERON-η WITH OLIGONUCLEOTIDES
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
EP1021726A1 (de) 2000-07-26
AU3986697A (en) 1998-03-06
DE69731983T2 (de) 2005-10-06
EP1021726B1 (de) 2004-12-15
US5989839A (en) 1999-11-23
WO1998008099A1 (en) 1998-02-26
DE69731983D1 (de) 2005-01-20

Similar Documents

Publication Publication Date Title
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
ATE435282T1 (de) Menschliche hämatopoietische stamm und vorläuferzellantigen und methoden zu dessen verwendung
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
ES2170220T3 (es) Procedimiento para detectar sustancias biologicamente activas.
EP0140322A3 (en) Polymer catalyst transducers and use thereof in test kits for analytical methods
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
ATE100150T1 (de) Verfahren zur bestimmung von physiologisch wirksamen substanzen.
EP1102988B8 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
NO950426D0 (no) Analyse for bestemmelse av protein i en biologisk pröve
ATE17262T1 (de) Verfahren zur quantitativen bestimmung von blutgerinnungsfaktor xii in humanplasma.
Onuma et al. Quantitative analysis of the proliferation of epidermal cells using a human skin organ culture system and the effect of DbcAMP using markers of proliferation (BrdU, Ki-67, PCNA)
SE9403833D0 (sv) Analysförfarande och kit
NO20051024L (no) Fremgangsmate for diagnostisering av multippel sklerose
ATE285076T1 (de) Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren
ES8707798A1 (es) Un procedimiento para analizar una muestra de tejido para determinar la presencia de antigeno de la hepatitis no a no b
ATE325890T1 (de) Verfahren zur bestimmung der ionenkanalaktivität einer substanz
ATE132896T1 (de) Methoden zur verwendung von an humanen klasse-ii- histokompatibilitätsantigenen mangelnden zellinien
NO920624L (no) Reagens for paavisning av fibrinolytisk aktivitet
DE69533200D1 (de) Verfahren zur prüfung von immunokompetenz
ATE283479T1 (de) Verfahren und testsatz zur bestimmung der analytkonzentration im blut
SU1389473A1 (ru) Способ прогнозирования землетрясений
Bock et al. Development of a new method of analysing chemotactic deactivation of human neutrophil granulocytes
ATE206167T1 (de) Verfahren und elektrochemisch-enzymatisches indikationssystem zur bestimmung von nitrit
DE69807410D1 (de) Auf Enzym-gegründetes Assay zur Bestimmung der Wirkung von exogenen und endogenen Faktoren auf Zellenergie-Bildung
ATE214160T1 (de) Überwachung der immunotherapie von malignen tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1021726

Country of ref document: EP

REN Ceased due to non-payment of the annual fee